IMVIF OTC

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DPX platform, specifically engineered to attack cells expressing survivin. This compound is currently advancing through Phase II clinical studies for diffuse large B-cell lymphoma, ovarian cancer, and a variety of solid tumors including those affecting the bladder, liver, and MSI-H positive types. It is also in Phase I investigation for breast cancer. Additionally, the company's pipeline includes DPX-SurMAGE, undergoing Phase I clinical evaluation for bladder cancer, alongside the development of DPX-COVID-19 and DPX-RSV for addressing infectious diseases. The entity, previously known as Immunovaccine Inc., formally adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its corporate headquarters in Dartmouth, Canada.